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Immunotherapy has revolutionised the treatment of cancer in recent years; significantly 
improving patient response and long-term survival. Though many immunotherapies 
focus on increasing the effector function of immune cells, the ability to generate and 
stimulate new tumour-specific immune cells has become an important topic for patients 
who do not respond to first line therapy. Previous work in our laboratory identified that 
intracellularly reversible conjugation of mode antigen ‘Ovalbumin’(OVA) to CpG B 
adjuvant improves the tumour specific response both in terms of immune cell activation, 
proliferation, and cytokine release, leading to complete tumour clearance in mice. This 
year I aimed to repeat this using the clinically significant melanoma antigen ‘gp100’ 
instead of OVA and to compare the use of CpG B adjuvant to CpG C adjuvant, which 
stimulates additional cytokine release, in the conjugate vaccine model. Using a 
combination of reversed phase high performance liquid chromatography (RP-HPLC) and 
cell culture, conjugates were produced and tested on their ability to activate Dendritic 
cells, induce their production of pro-inflammatory cytokines and induce T cell response 
in co-culture. Purification of gp100 conjugates was unsuccessful via RP-HPLC and 
testing reverted to the OVA model when comparing CpG conjugates. In antigen 
presenting cells, both conjugates induced similar levels of activation and antigen 
presentation but had unique cytokine profiles, with both conjugates trending towards 
higher levels of IL-1β and IL-12p70. Both CpG B-OVA and CpG C-OVA conjugates 
also induced a strong tumour-specific response with increased CD4+ and CD8+ T cell 
proliferation and significantly increased CD8+ T cell IFN-γ secretion. With these results 
in mind, both conjugates appear as strong candidates for therapeutic vaccination trials as 
either a monotherapy or a combined therapy with Checkpoint Blockade or Adoptive T 
iv 
 
Cell Therapy. In vivo testing using the CpG C construct is needed to assess its efficacy 
over CpG B. 
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1.1 Chapter 1 – Introduction 
 
1.1.1 Cancer overview 
 
Cancer is one of the leading causes of death in the developed world. With over 14.1 
million new cases in 2012 alone, the search for new and effective treatment options 
remains a challenge for oncologists and researchers alike (1). Cancer is a genetic and 
often age-related disease in which the accumulation of mutations within a cell enable it 
to grow and behave abnormally in its residing tissue (2-4). As cells increase in number, 
they form a benign mass or ‘tumour’ that is encapsulated in a fibrous membrane. 
Continual growth and mutation can eventually lead to new cell characteristics that enable 
tumours to invade the surrounding tissue causing different pathologies. These 
invasive/malignant tumours are commonly known as ‘cancer’. Designing new treatments 
for malignant tumours is an ongoing challenge as they are present in multiple tissues, 
originating from healthy cells. Similarities to healthy cell markers and receptors limit 
treatment as ‘selective toxicity’ cannot easily be obtained (5). Treatments such as 
chemotherapy can produce side effects associated with healthy, as well as malignant, cell 
death (6). These side effects negatively affect patient quality of life and treatment 
outcomes. Until 2011, few treatments were available for cancers such as melanoma and 
those available offered little survival benefit. Since the introduction of targeted molecular 
therapies to treat cancer, there have been significant increases in patient survival and 
remission rates (7-9). Immunotherapies such as Ipilimumab and Pembrolizumab, 
(immune checkpoint inhibitors) have also revolutionised metastatic melanoma treatment. 
Immune checkpoint inhibitor approval has also renewed interest in other immune based 
therapies including therapeutic vaccines. This article will review the current and future 




treatments and other immunotherapies. I will also describe the immune response to 
cancer and the aim of my research; to determine the best combination of gp100 peptide 




Melanoma is described as the benign or malignant growth of melanocytes that reside in 
the skin. Whilst not as common as other skin cancers, melanoma has the highest mortality 
rate at 65%, killing around 50,000 people worldwide each year (10). Identification of 
melanoma occurs through microscopic analysis of patient biopsies. This is followed by 
a more thorough diagnosis including B- rapidly accelerated fibrosarcoma (BRAF) 
mutation status, tumour staging and tumour grading to determine the therapeutic regime 
(11). Tumours are staged according to their thickness in millimetres, degree of spread to 
local lymph nodes and metastatic spread to other tissues. Grading of tumours depends on 
their appearance and behaviour compared to normal cells in the tissue, with grade-I 
tumours being slow growing and similar to healthy cells and grade-IV tumours being 
poorly differentiated and displaying rapid growth. Most benign melanomas are low-stage 
and grade and thus can be removed surgically with few complications. Despite the 99% 
cure rate of benign tumours in stage I-III via surgical resection, invasive stage III and IV 
can often be fatal, with a 5-year survival rate of less than 10% (10, 12-14). At this point, 
surgical removal is redundant as the tumour is present in multiple tissue layers and no 





1.1.3 Conventional treatments for Metastatic Melanoma 
 
Conventional treatments for malignant melanomas include radiation therapy, 
chemotherapy, and immunotherapy. These will be discussed further below. 
 
1.1.3.1 Radiation therapy 
 
Radiation therapy has had limited success in the treatment of metastatic melanoma, yet 
remains a treatment option; given its ability to reach tumours inaccessible by surgery. 
Used in 1-6% of melanoma cases, it is often used as a palliative measure, offering little 
survival benefit in practical terms. Despite this, radiation therapy has been shown to have 
an abscopal effect on distant tumours, suggested to be immune mediated (16, 17). For 
this reason, combination with immunotherapies has been considered. A study by Safwat 
et al showed a response rate of 71% in combination with IL-2 (18, 19). Ipilimumab 
combination has also been trialled and more than tripled the median survival time; 




For over 40 years, chemotherapy has been the standard treatment for metastatic 
melanoma. Until 2011, the alkylating agent, Dacarbazine was the main treatment for 
most cases; producing response rates of 10-20% and poor overall survival (21-24). Since 
2011, the approval of targeted molecular therapies, such as BRAF inhibitors, 
Vemurafenib and Dabrafenib, has successfully increased patient response and survival 




pathway that mediates tumour growth. BRAF mutations are present in over 50% of 
melanoma cases and so are an ideal molecular target for therapy (3, 7, 14, 25). Though 
BRAF inhibitors can improve progression-free survival, (PFS), in the short term, 
resistance mechanisms, which develop within tumours, limit their long-term efficacy. 
The use of mitogen-activated protein/extracellular signal-regulated kinase (MEK) 
inhibitors, such as Trametinib in addition to BRAF inhibition, have overcome this 
problem (3, 26). These inhibit resistance mechanisms developing downstream in the 
BRAF signalling pathway (25). Combined BRAF and MEK inhibitor therapies have 
successfully increased PFS (8, 27). Although chemotherapy has had poor success in the 
past, newer targeted therapies, have greatly increased patient survival; particularly when 




Immunotherapies for cancer have focused on enhancing the number and activity of 
effector T cells. This is achieved through: the administration of cytokines to the tumour 
site, which directly act on T cells, blockade of known T cell inhibitors, as well as 
production of vaccines that aim to enhance antigen presenting cell (APC) activation and 
their presentation of tumour peptides. One first-line treatment for metastatic melanoma 
involves the administration of intra-lesional IL-2 into the tumour site (28). Although this 
cytokine induces both CD8+ and CD4+ T cell proliferation, response rates for IL-2 have 
been low, with some suggesting that IL-2 administration may enhance suppressive T 
regulatory cell activity; which dampens the effector response (29). Severe side effects 
such as vascular leakage also limit its use. Despite this, IL-2 administration has shown 




31). The most successful immunotherapy to date is Immune Checkpoint Blockade. This 
involves the use of monoclonal antibodies that target suppressive mechanisms that limit 
effector T-cell responses. Ipilimumab, an anti-cytotoxic T-lymphocyte-associated 
protein 4 (CTLA4) antibody and Pembrolizumab, an anti-programmed cell death protein 
1, (PD1) are examples of these. In combination, these therapies have produced response 
rates as high as 60% and increased patient survival (9, 32).  
 
1.2 Immune response to cancer 
 
1.2.1 Tumour associated antigens 
 
The key step in generating anti-tumour immune responses is the recognition of tumour-
associated antigens (TAAs). These are tumour-expressed compounds that potentially 
activate the immune system. Immunotherapy design for cancer has traditionally focused 
on identifying TAAs and facilitating their uptake by APCs. APCs play an important role 
in immunity by processing TAAs and presenting them to TAA-specific effector T cells 
(33). These then migrate from the lymph node to wider tissue cells; terminating cells 
expressing these TAAs. Melanoma is extensively modelled in immune-based cancer 
research due to the identification of several TAAs and their unique immunogenicity, 
compared to other cancers. As such, many studies have shown some melanoma patients 






1.2.2 Tumour antigen uptake and presentation 
 
Cancers originate from healthy cells that accumulate mutations and behave abnormally 
in their tissue of origin. The first step in generating a tumour specific response is detection 
of these abnormal cells by the immune system. The release of stress signals and the 
expression of mutated self-proteins by tumours enables this detection. APCs within the 
tissue, such as macrophages and dendritic cells (DCs), are the first to encounter these 
proteins through phagocytosis, receptor-mediated endocytosis and macropinocytosis of 
material from their external environment (36-38). Peptides are deemed immunogenic if 
they, or compounds associated with them, stimulate pattern recognition receptors (PRRs) 
which activate a cascade of intracellular signals. The best described PRRs are the Toll-
like receptors, (TLRs), which are expressed on the cell surface and within endocytic 
vesicles (39). Products such as Heat Shock Proteins (HSP) produced by necrotically 
dying cells, under-methylated bacterial DNA (CpG) and Lipopolysaccharide, all activate 
TLRs (40). Signalling of TLRs leads to APC activation including production of pro-
inflammatory cytokines such as IL-1β, IL-6 and TNF-α, upregulation of cell surface 
proteins such as major histocompatibility complex (MHC), and expression of 
costimulatory molecules CD80, CD86 and CD40 (39, 41-43). After intracellular uptake 
by APCs, TAAs are broken down into peptides in the endo-lysosomal compartments by 
a combination of low pH and degradative enzymes such as cathepsins (36, 38, 44, 45). 
These TAAs are then loaded onto MHC-II molecules and presented on the cell surface 
(46, 47). TAAs within the cytoplasm can be presented onto MHC-I molecules after 
ubiquitination. This process tags them for degradation by the proteasome, a multi-
catalytic complex that degrades intracellular proteins (48). Exogenous TAAs may also 
be fed into this MHC-I pathway, through a process called cross-presentation which is 




pathways and enables APCs to present antigen on both MHC-I and II, to effector T cells. 
Peptides in the vacuolar pathway are produced in lysosomes, mediated by the enzymatic 
activity of cathepsins. They are then loaded onto MHC-I that enters during receptor 
recycling and endosomal MHC-I transport to the cell membrane (49, 50). The cytosolic 
pathway involves transport of peptides into the cytosol, mediated by the proteins SEC61 
and p97. These peptides are then degraded by the proteasome and loaded on MHC-I 
within the endoplasmic reticulum (ER) (51). Alternatively, this may involve the delivery 
of ER proteins including; transporter associated with antigen processing (TAP) to the 
phagosome by protein Sec22B. This then facilitates proteasome-processed peptide 
transport back into the phagosomes, before loading onto MHC-I (52, 53).  
 
1.2.3 T cell activation and anti-tumour activity 
 
To activate a T cell, APCs must produce three unique signals. Together these drive T cell 
proliferation and polarisation to certain phenotypes, each with unique activity (54). After 
TAA acquisition, DCs with peptide-loaded MHC migrate to the draining lymph node 
where they present antigen on MHC-II to CD4+ T cells and MHC-I to CD8+ T cells. 
This antigen-specific process produces the first signal for T cell activation; full activation 
is not achieved until co-stimulatory molecules also bind (55). T cell ligands such as cell 
surface protein CD28 bind to CD80 and CD86 on APCs producing a co-stimulatory 
signal leading to T cell clonal expansion (signal 2). As these cells differentiate, they form 
a small memory T cell population that protects against secondary tumour challenge and 
an effector cell population. Pro-inflammatory signals from the APC also act on the T cell 
influencing its polarisation to phenotypes such as Th1, Th2 and Th17 (signal 3). In 
cancer, the cytokines IL-12 and IL-18 released from APCs, act together to cause a Th1 




to their ability to produce IFN-γ and tumour necrosis factor (TNF)-α which enhance 
CD8+ T cell cytotoxicity (60). In addition to CD4+ T cells, APCs may activate CD8+ T 
cells through peptide presentation on MHC-I molecules, in conjunction with co-
stimulatory proteins and cytokines similar to CD4+ activation (54, 61). CD8+ T cell 
activation leads to differentiation into effector cells that use both indirect and direct 
methods to kill tumours. Indirect killing involves the release of TNF-α and IFN-γ at the 
tumour site which can induce cellular apoptosis (62, 63). There are two methods of direct 
killing; firstly, recognition of the foreign peptide on tumour MHC-I can induce secretion 
of perforin and granzyme molecules that create pores in the cell membrane and activate 
intracellular caspases, that initiate apoptosis. Secondly, effector CD8+ cells may induce 
cell death through expression of their CD95L protein, which binds to the CD95 receptors 
on tumour cells also initiating apoptosis (64, 65). Following activation, both effector T 
cells express suppressive receptors such as CTLA 4, which competes with CD28 for 
costimulatory molecule binding, and PD-1 that can induce apoptosis when it binds to PD-
L1. Expression of these molecules increases overtime in tumour sites with chronic 








Figure 1: The three steps in generating an anti-tumour response 1) Antigen presenting cells take up tumour 
antigens, activate and migrate to the lymph node. 2) APCs process these and present them on MHC-I to CD8+ T 
cells and on MHC-II to CD4+ T cells, activating them in addition to co-stimulatory signals 3) Activated T cells 
clonally expand and migrate to the tumour site eliciting anti-tumour activity via cytokine release and induction of 











1.3 Other Effector Immune cells 
 
1.3.1 B cells 
 
B-lymphocytes (B cells) also play a role in anti-tumour immunity. As adaptive immune 
cells, B cell responses are important in tumour clearance through their ability to act as an 
APC, and their production of TAA specific polyclonal antibodies (68). TAA-specific 
polyclonal antibodies play a key role in anti-tumour immunity through two mechanisms. 
Firstly, these antibodies, specifically Immunoglobulin M (IgM), are potent stimulators 
of the classical pathway of the complement cascade. This cascade consists of a series of 
innate catalytic proteins that can act as pro-inflammatory mediators or directly lyse cells 
through formation of a membrane attack complex on their surface (69, 70). IFN-γ 
produced by T cells also stimulates B cells, inducing isotype switching to production of 
IgG2 titres. As well as complement activation, polyclonal antibodies also induce Natural 
killer cell (NK) mediated cell death. NK cells are lymphoid cells that play a key role in 
the clearance of tumours that do not express MHC. This occurs through a process called 
antibody dependant cell mediated cytotoxicity (ADCC), in which antibodies bound on a 
cell’s surface induce secretion of perforin and granzyme by NK cells leading to cell lysis 
(71). This plays a pivotal role in the efficacy of several monoclonal antibody based 
treatments and in the cytotoxic effects of some chemotherapies (72, 73). 
 
1.3.2 Natural Killer cells 
 
NK cells play a crucial role in tumour surveillance and clearance, without the need for 
APC stimulation, and patrol the tissue and blood searching for cellular markers of stress 




characteristic feature of virally infected cells and an important resistance mechanism 
used by tumour cells to avoid CD8+ killing (74). NK cells that recognise 
stressed/malignant cells activate and induce apoptosis using perforin and granzyme or 
CD95L like CD8+ cells (75).Activation is also triggered by pro-inflammatory cytokine 
release such as IL-12, IL-18, IL-15 and IFN-β from APCs and epithelial cells (58, 72, 
76, 77). These cells may also release chemokines, which signal and recruit NK cells to 
the tumour site. Tumour cell killing by NK cells is also triggered by the presence of 
antibodies bound to the tumour via ADCC (see above) (72). Some tumour cells may 
express ligands on their surface such as ULBP1 and MICA/B which are recognised by 
NK receptors such as NKG2D leading to tumour cell killing. 
 
1.4 Cancer vaccines 
 
Cancer vaccines have shown significant promise in the treatment of melanoma; both in 
combination and as a monotherapy. They are formulations of tumour peptide that are 
delivered to APCs to increase their activation of T cells and resulting number of tumour 
infiltrating lymphocytes (TILs), a strong determinant of patient prognosis (78, 79). Used 
in conjunction with other therapies including intra-lesional IL-2 and checkpoint 
inhibitors, vaccines have been shown to augment effective long-term memory responses 
whilst improving patient outcome. In the case of melanoma, several vaccines have been 
trialled each using different tumour antigens. One phase 1 study by Slingluff et al, which 
used the melanoma glycoprotein ‘gp-100’(280-288) in Montanide, an oil in water 
emulsion, showed an overall survival rate of 75% at 5 years (80). The use of 
differentiation antigens like gp100 show promise for vaccine treatment given their 




T cells 1 (MART-1) and gp100 in oil emulsion showed similar response rates (82). 
Vaccines use in the treatment of malignancy continues to be investigated, with the aim 
of improving efficacy; these include addition of TLR agonists, bio-conjugation strategies 
and nanoparticle delivery, discussed below. 
 
1.4.1 TLR agonists 
 
TLR agonists have long been proposed as a mechanism to improve vaccine efficacy. 
Activation of TLRs enhances T-cell responses by inducing upregulation of co-
stimulatory molecules on APCs and release of pro-inflammatory cytokines (83, 84). TLR 
agonists such as Imiquimod and CpG oligodeoxynucleotides (ODN) have been involved 
in several cancer-based therapies, often as an addition to tumour-associated peptides (85, 
86). Imiquimod in particular, has been used extensively in murine trials. As a TLR7/8 
agonist, Imiquimod stimulates production of type 1 interferons (IFN-α/β) by DCs, 
leading to Th1 polarisation and a robust CD8+ response. When administered both 
topically and/or intradermally along-side peptide vaccines, Imiquimod led to significant 
increases in TILs and mononuclear cells at the tumour site; compared to controls (85). 
CpG ODNs have also shown promise mediating tumour-specific responses with CpG 
Class B, characterized by its stimulation of B cells, NK cells and CD8+ T cells; currently 
being used in several treatments (86). As a method to enhance therapeutic potential, CpG 
has also been co-delivered to DCs; alongside tumour antigens. This strategy has shown 
to increase both tumour specific CD8+ and NK cell numbers more than independent 
delivery (87, 88).  Recent studies propose the use of Class C CpG adjuvants; given their 
ability to stimulate production of both B cell-acting cytokines such as IL-6 as well as 
type 1 interferons similar to Imiquimod. The administration of CpG Class C in 




in a study by Cerkovnik et al (89). Another study by Yang L et al showed similar results 
with effective tumour rejection when injected to the draining lymph nodes of mice with 
breast cancer. This effect was greater than Class B CpG ODNs (90). In sum, the use of 
TLRs effectively boosts anti-tumour responses in a variety of cancer models. In 
designing vaccines, one should consider co-delivery with TAAs, as pre-clinical studies 
have shown this can further enhance the immune response. 
 
1.4.2 Co-delivery mechanisms 
 
Although TLR agonists have produced promising results when administered singularly 
and as a mixture with TAAs, more effective co-delivery mechanisms have been 
proposed. These, including bio-conjugates and nanoparticles facilitate delivery of both 
TAA and adjuvant to the same DC; inducing full activation, enhanced cross-presentation, 




Bio-conjugation strategies have extensively been used to co-deliver TAAs and adjuvants 
to the same APC. These often involve direct and stable conjugation to proteins or 
antibodies; this has had mixed results in murine models.  
The majority of bio-conjugations involve reacting primary amine groups on 
proteins/peptides with N-Hydroxysuccinimide (NHS) ester groups on other molecules, 
which form a stable amide bond, resistant to hydrolysis (91, 92). The popularity of amine-
based conjugation stems from its location within proteins, on both the N-terminus and 




pH. As a result, conjugation can be performed whilst still maintaining protein structure 
and biological activity. 
 
Thiol chemistry has also been utilised for bio-conjugation, though it is not as popular as 
amine modification. The limited availability of cysteine groups in biological molecules 
of interest does however enable more selective conjugation (93). Despite this, thiol 
groups, particularly disulphide bonds, are key components of many proteins and 
modification can disrupt normal biological function. This limits their application, 
particularly in conjugations with proteins such as antibodies, as it may alter their binding 
specificity and solubility. Functional groups including amines can be modified into thiols 
increasing their number for conjugation and avoiding functional disruption. 
 
Aldehyde functional groups can also be used in bio-conjugation. Their absence from 
most biological compounds however, limits their utilisation in direct conjugation 
strategies. Despite this, aldehyde groups are often used in linker molecules introduced to 
biological molecules via modified amine groups etc. An example of this is succinimidyl 
4-formylbenzoate, which contains both an NHS ester and an aromatic aldehyde. This 
NHS ester conjugates onto biological molecules making the aromatic aldehyde available 
for additional linkages. Aldehyde groups can be reacted with free amino groups forming 
unstable Schiff’s bases requiring additional reductions to stabilise the linkage (94). More 
commonly though, aldehydes are reacted with hydrazine molecules to form stable 
hydrazone bonds. Innovative linker technologies at Solulink have further improved these 
conjugates by producing linkers with aromatic aldehydes and hydrazines, which when 
combined, form a highly stable bis-arylhydrazone bond. These conjugated products can 




Recently, the utilisation of reversible conjugates has been investigated in vaccine 
formulation. These conjugates are designed to cleave intracellularly due to differences in 
reductive environment or pH (96, 97). Reversible conjugates offer several advantages 
over stable formulations and non-conjugated antigen-adjuvant mixtures. Firstly, their 
sensitivity to intracellular conditions often provides them with stability extracellularly, 
where conditions do not favour cleavage. Additionally, reversibility within the cell 
enables each constituent to dissociate and activate their respective receptors; with less 
hindrance than stable conjugates. This is particularly evident when each receptor lies in 
different cellular compartments. Immunologically, reversible conjugates may also 
facilitate cross-presentation of antigen to MHC-I. Studies by Nembrini et al, Hirosue et 
al and Flannery et al, demonstrated that OVA reversibly conjugated to nanoparticles and 
polymeric carriers respectively, caused significant increases in MHC-I presentation and 
CD8+ T cell responses; compared to stable conjugates (96, 98, 99). Research in our 
laboratory using soluble Glutathione (GSH) sensitive OVA-CpG conjugates also showed 
an increased CD8+ response and enhanced anti-tumour immunity in mice challenged 






Figure 2: Effect of reversible GSH sensitive conjugate on APC. After cellular uptake, the higher concentration of 
glutathione intracellularly leads to reduction and cleavage of the linker. As the linker is cleaved the tumour antigen 
is released, processed and presented onto MHC. Simultaneously, the TLR agonist activates TLRs in the endosome 
leading to increased expression of co-stimulatory molecules (CD86, CD40) and pro-inflammatory cytokines. 
1.4.4 Nanoparticles 
Though bio-conjugates remain a viable strategy for co-delivery of TAA and adjuvant into 
the same cell, they rely heavily on the stability of each component and its ability to resist 
degradation in the extracellular environment. Nanoparticles (NPs) are one solution to this 
challenge and are employed to protect sensitive products targeted for intracellular uptake. 
This APC uptake is also significantly greater than soluble vaccines (101). 
Many compounds are conjugated directly onto nanoparticles for this very reason as well 




substances smaller than 1000nm including virus-like particles (VLPs) and polymeric 
NPs; VLPs being the most well-known (102). As self-assembled virus shells, VLPs are 
popular due to their ease of production and the variety of options for presenting TAAs of 
interest. Antigens can be conjugated onto the VLP, packaged inside the VLP or the 
antigen sequence can be added to the VLP sequence and be expressed alongside their 
capsid proteins. As well as this, the highly repetitive structure of VLPs has shown to 
induce humoral immune responses (103).VLPs have been extensively used in several 
vaccine trials in combination with TAAs, generating strong CD8+ responses and Th1-
associated IgG2 production (104).  
Polymeric NPs are another delivery mechanism commonly used, with a reputation for 
superior biodegradability and biocompatibility. These structures are made from a variety 
of compounds including poly (g-glutamic acid) and poly (D, L-lactic-coglycolic acid). 
Polymeric NPs have been promising, with studies showing the induction of a strong 
humoral and cell mediated immune responses when antigen is conjugated onto them (96, 
105). A study by Silva et al showed that encapsulation of TAAs in combination with 
TLR agonists also induces a strong anti-tumour response, with delivery of CpG and 
gp100 (209-217) enhancing in vivo immunity to melanoma (106). Current polymeric NP 
vaccines aim at further improving delivery through targeted localisation to the draining 
lymph nodes, a key site for APC-T cell interactions and thus induction of an adaptive 
anti-tumour response. A promising new nanoparticle is the ISCOMATRIX adjuvant 
composed of a mixture of phospholipid, Quillaia saponaria extract and cholesterol that 
form a cage-like structure. Pre-clinical tests using OVA and TLR agonists with 





1.5 Current research and aim 
 
This introduction has aimed to give insight into the current treatments for melanoma and 
the potential of therapeutic vaccination as an effective immune therapy. With current 
challenges such as improving immunogenicity and delivery of soluble cancer vaccines 
acknowledged, this study aims to test new soluble vaccine strategies using clinically 
relevant TAAs. Though current soluble vaccines have significantly less uptake than other 
strategies, such as nanoparticles, delivery mechanisms can be improved. For example the 
use of CpG conjugates enhances cellular uptake 50-fold compared to mixtures, due to its 
interaction with the DEC205 receptor on DCs (100, 108). 
Research in our laboratory has previously demonstrated that intracellular cleavable 
conjugates of OVA and Class B CpG ODN 1668 elicit strong anti-tumour responses in 
mice (100). I aim to assess the efficacy of this strategy when using the TAA ‘gp100’ as 
opposed to OVA. I also aim to determine the optimal amino acid length of gp100 for use 
in this conjugate by comparing two peptides, gp100 (25-33) which requires no additional 
processing and gp100 (19-39) which does. Class B CpG ODN 1668 will also be brought 
under question as the optimal CpG class for this strategy, and will be compared to Class 
C CpG ODN 2395, which induces production of IFN-α in addition to the cytokines 
induced by 1668. 
To understand the mechanism of these conjugates’ anti-tumour effect, I will measure the 
expression of MHC-II, CD40 and CD86 and cytokine release (IL-12, IL-1β, IL-6, TNF-
α, IFN-α) after pulsing DCs with either stable or reversible conjugates. This will give an 
indication of the level of activation within these cells and therefore their propensity to 
activate T cells. Pulsed DCs will then be co-cultured with T cells for 72 hrs and T cell 
proliferation and IFN-γ secretion will be measured giving a complete view of the 




function of CD8+ T cells after co-culture using an in vivo cytotoxicity assay. I 
hypothesize that reversible conjugation of Class C CpG ODN 2395 to gp100 (25-33) will 
elicit the strongest immune response characterized by greater BMDC activation and 
cytokine release and greater CD4+ and CD8+ T cell proliferation and IFN-γ release. 
 
To conclude, research into therapeutic cancer vaccination remains ongoing. Although 
currently not a first line treatment for cancer, its potential in combination with other 










 Chapter 2       





2.1 Production of CpG-Gp100 conjugates 
 
2.1.1 Acquisition of CpG oligonucleotides and Gp100 peptides 
 
CpG oligonucleotides were purchased and custom synthesised by GeneWorks Pty Ltd, 
Hindmarsh, AUS (CpG 1668) and Integrated DNA Technologies Inc., Iowa, USA (CpG 
2395). Phosphorothioated (PT) CpG 1668 (5’ TCCATGACGTTCCTGATGCT 3’) was 
modified with a 3’ amino (NH2) group whilst PT CpG 2395 (5’ 
TCGTCGTTTTCGGCGCGCGCCG 3’) was modified with a 5’ amino group. Both 
oligonucleotides were bought in lyophilised form and stored at 4 °C. At time of use, CpG 
ODNs were suspended in Modification buffer (0.1 M Na2HPO4, 0.15 M NaCl pH 8.0) 
and OD260/μl measured using the Nanodrop 1000 (NanoDrop, Version 3.7.1, Thermo 
Fisher Scientific, Waltham, MA, USA). Approximately 30-50 nmol of each CpG was 
used per conjugation for modification steps. Gp100 peptides 25-33 (KVPRNQDWL) and 
19-39 (CAVGALKVPRNQDWLGVPRQL) were purchased in lyophilized form from 
Mimotopes Pty Ltd, Victoria, AUS. Each was resuspended in modification buffer and 
separated into 30 μl aliquots at approx 3.07 mg/ml and 6.89 mg/ml respectively. Aliquots 
were stored at -20 °C until use. 
 
2.1.2 Solulink two-linker strategy 
 
Conjugation of gp100 to CpG involved a two-linker strategy designed by Solulink. 
Firstly, aromatic aldehyde linkers succinimidyl-4 formylbenzoate (S-4FB, Solulink Inc., 
San Diego, CA, USA) or succinimidyl-SS-4 formylbenzoate (SS-4FB, Solulink) are 




linker, react with the NH2 group to form a stable amide bond. After reaction, and removal 
of excess linker, the rate of modification is measured through addition of 2-
Hydrazinopyridine solution (2-HP, Solulink). This reacts with the aromatic aldehyde and 
enables colorimetric analysis of each linker based on its absorbance at 360 nm. This 
measurement is then combined with the OD260/ µl of the modified CpG in the equation 
below, to give the molar substitution ratio (MSR) of the reaction. MSRs of 0.8-1.2 
indicate a successful reaction. The modified CpG was then reacted with succinimidyl 6-
hydrazinonicotinate acetone hydrazone (S-HyNic, Solulink). This linker contains an 
aromatic hydrazine which reacts with the aromatic aldehyde of S/SS-4FB to form a stable 
bis-aryl hydrazone bond. This can then be quantified based in its absorbance at 345 nm. 
Finally, gp100 is added to the construct. Primary amine groups on the N terminus of 
gp100 and on lysine residues react with the NHS ester group present on the S-HyNic of 
the modified CpG. This then forms another amide bond and completes the conjugation. 
A detailed method of each steps is provided below. 
 
𝑀𝑆𝑅 =












Figure 3: Schematic of CpG reversible conjugation to gp100 peptide. Firstly, CpG is reacted with SS-4FB linker, 








2.1.3 Modification of CpG Oligodeoxynucleotides 
 
Concentrations of CpG were measured by their UV absorbance at 260 nm using 
Nanodrop 1000 and each suspended into 1 x Modification buffer. CpG was modified by 
adding 4 molar equivalents of 20 mg/ml S-4FB (Solulink) or SS-4FB (Solulink) linker 
dissolved in dimethyl sulphoxide (DMSO, Thermo Fisher Scientific) at volumes supplied 
by the peptide/oligo calculator on the Solulink website. At least 30 nmol of CpG was 
used for each modification to ensure a sufficient product yield for further conjugation 
steps. This also ensured sufficient linker modification. CpGs were then left to react at 
room temperature for 2 hrs in Eppendorf tubes. The resulting products were then 
exchanged into conjugation buffer (0.1 M Na2HPO4, 0.15 M NaCl pH 6.0) and 
centrifuged (Heraeus™ Fresco™ 17 Microcentrifuge, Thermo Fisher Scientific) five 
times at 13000 x g 4 °C for 15 mins using 3 KDa molecular weight cut off (MWCO) spin 
filters (Amicon Ultra - 0.5 ml Centrifugal Filters, Regenerated Cellulose 3000 NMWL, 
Millipore, Cork, IRL) to remove excess linker. The samples were then reverse spun at 
1500 x g for 2 mins 4 °C by inverting the filter and placing into a new Eppendorf tube. 
The Molar Substitution Ratios (MSR) were then measured by adding 2 μl of each 
modified CpG to separate tubes containing 18 μl of 0.5 mM 2-HP solution (Solulink) in 
0.1 M 2-(N-morpholino) ethanesulfonic acid (MES) buffer. This was incubated for 30 
minutes at 37 °C followed by A360 nm measurement on the Nanodrop 1000. 2-HP allows 
colorimetric analysis of the aromatic aldehyde present on the S-4FB and after removal 
of excess linker via centrifugation, gives an indication of the level of CpG modification. 







2.1.4 S-HyNic Modification 
 
SS-4FB and S-4FB-modified CpG oligonucleotides were treated with a 40-fold molar 
excess of S-HyNic (Solulink) dissolved in DMSO at a concentration of 20 mg/ml. 
Volume added was determined by the peptide/oligo calculator on the Solulink website. 
Solution was briefly vortexed and then left to react for 2hrs at room temperature. 
Following reaction, the sample was transferred to Amicon 500 spin filters, exchanged in 
conjugation buffer, and centrifuged five times at 13000 x g for 15 mins at 4 °C to remove 
any unconjugated S-HyNic. Gp100 peptides were then added to individual modified CpG 
tubes at a four-fold molar excess along with turbolink buffer (0.1 M Na2HPO4, 0.15 M 
NaCl, 0.1 M aniline pH 6.0) at a volume determine on the Solulink calculator (~5-10 μl) 
to catalyse the reaction. This was then left to react for 2 hrs. The final product was then 
spun again five times at 13000 x g for 15 mins at 4 °C in conjugation buffer to remove 
any unreacted gp100 peptide. 
 
2.1.5 Analysis of gp100 peptide conjugates 
  
Gp100 peptide conjugates were analysed using Reverse Phase High Performance Liquid 
Chromatography (RP-HPLC) on an Agilent Technologies 1290 Infinity Chromatograph 
(Agilent Technologies, Santa Clara, CA, USA). Firstly, 10 μl of each sample was added 
to individual HPLC vials with 20 μl of Phosphate Buffered Saline (PBS) (Appendix 1). 
Individual Gp100 peptides were tested at concentrations of 50, 100, 250 and 500 μg/ml 
and CpG oligonucleotides at 0.5 μM, 2 μM, 4 μM, 8 μM, 10 μM and 100 μM. Conjugates 




This ranged from 0.3 mg/ml to 1.3 mg/ml. Before samples were run, the HPLC was 
equilibrated overnight using 65% acetonitrile (ACN). The column, (Thermo Scientific™ 
Hypersil™ BDS C18 100 x 4.6mm, 3 μm), was then loaded onto the machine and UV-
lamp set to measure 210 nm, 214nm, 220 nm and 280 nm. The column was then 
equilibrated in 50% ACN + 50% MilliQ water for 2 hrs before sample loading. Samples 
were run on the HPLC for 45 mins at a flow rate of 0.5 ml/min, with an injection volume 
of 10 μl and a column temperature of 25 °C. Lines were periodically washed every 15 
mins with seal wash (10% isopropyl alcohol). Mobile phase A was 0.1% Trifluoroacetic 
acid (TFA) in MilliQ and mobile phase B was 0.1% TFA in 100% ACN (see Mobile 
phase elution gradient table 1). 3D spectral analysis was then performed on each sample 





Table 1: Initial RP-HPLC Elution gradient 
Time (min) % Mobile phase A % Mobile phase B Flow rate 
0 90 10 0.5 ml/min 
20 56 44 0.5 ml/min 
40 10 90 0.5 ml/min 
41 90 10 0.5 ml/min 
45 90 10 0.5 ml/min 
 
Following initial testing, the run time was adjusted to 35 minutes (see table 2 for elution 
gradient). 
 
Table 2: Modified RP-HPLC Elution gradient 
Time (min) % Mobile phase A % Mobile phase B Flow rate 
0 90 10 0.5 ml/min 
20 72.5 27.5 0.5 ml/min 
30 50 50 0.5 ml/min 







2.1.6 Purification of OVA 
 
Lyophilised Chicken Egg Ovalbumin (OVA) (purity ≥98 %, Sigma-Aldrich) was first 
weighed and dissolved in modification buffer (Appendix 1) via both vortexing and 
sonication. OVA, at approximately 15 mg/ml, was then purified using size exclusion 
chromatography (SEC) via Shimadzu High Performance Liquid Chromatography 
System (HPLC, Shimadzu, Columbia, MD, USA) using a Superdex™ 200 10/300 GL 
SEC column (GE Healthcare Bio-Sciences, Uppsala, SE). Modification buffer 
(Appendix 1) was used as the mobile phase after 2 hrs equilibration in the column and 
the flow rate was set to 0.5 ml/min. Each sample was loaded onto the column at an 
injection volume of 500 μl at room temperature. Purified OVA was then identified via 
its absorbance at 280 nm on the UV-Vis detector and collected at an elution time of 35 
minutes. OVA was then concentrated using Vivaspin® 6 spin filtration (3 kDa MWCO, 
GE Healthcare UK Ltd., Little Chalfont Buckinghamshire, UK) in a fixed angle swing 
bucket centrifuge (5415R centrifuge, Eppendorf AG) at 3500 x g for 30 mins to a volume 
of 300 μl. A280 was then measured in triplicate and mean averaged using Nanodrop 1000 




2.1.7 OVA Modification 
 
Modification of OVA was performed similar to CpG modification, with the exception 
that S-HyNic was used as the linker molecule at 30 molar equivalents to OVA. The MSR 




Solulink) in 0.1 M MES buffer to 2 μl of the S-HyNic modified OVA. Colourimetric 
analysis of the aromatic hydrazine on the S-HyNic molecule was then performed via 
A360 nm measurement on the Nanodrop 1000. 
 
2.1.8 OVA-CpG Conjugation 
 
Modified CpG was reacted at a 4 molar excess with modified OVA. SS-4FB modified 
CpG and S-HyNic modified OVA were mixed at concentrations supplied by Solulink, to 
ensure sufficient product was formed, and Turbolink buffer (Appendix 1) was added to 
catalyse the reaction. This was left to react for 2 hrs at room temperature. Conjugates 
were then purified from any unreacted products via SEC via the Superdex™ 200 10/300 
GL SEC column (GE Healthcare) at an elution time of ~ 27 minutes using PBS as the 
mobile phase. This was then concentrated using Vivaspin® 6 similar to OVA purification 
(see above).  
 
2.1.9 Quantification of conjugates 
 
Conjugate concentration was measured using a combination of A345 nm measurement 
and Quant-iT assay. Following reaction and concentration via Vivaspin® 6, A345 nm 
was measured for each conjugate using the Nanodrop 1000. This measures the presence 
of hydrazone bonds between SS-4FB-modified CpG and S-HyNic-modified OVA, and 
indicates if the reaction was successful. OVA concentration within the conjugate samples 
was measured using Quant-iT Protein Assay Kit (Thermo Fisher Scientific) via 




buffer and 200 μl was added to 18 wells of a black 96 well microplate. Standard 
concentrations of Bovine serum albumin (BSA) (0, 0.25, 0.50, 100, 200, 300, 400 and 
500 ng/μl) (10 μl) and each conjugate (5 μl) were then added to separate wells in duplicate 
and mixed by pipetting up and down. The plate was then run on a POLARStar Omega 
microplate reader (BMG Labtech GmbH, Ortenberg, Germany) at a wavelength of 
490/545 nm. Results were plotted on excel to form a standard curve and from this, the 
concentration of OVA in each conjugate was estimated in mg/ml. Measurements from 
both A345 nm and Quant-iT were then combined to determine the conjugation ratio of 












2.1.10 Analytical Size Exclusion Chromatography of CpG-OVA 
conjugates 
 
Prior to sample loading, an Agilent Technologies 1290 Infinity Chromatograph was 
briefly purged using 10% Methanol solution to remove any residual salts. Lines were 
then washed for 2 hrs in MilliQ water. A Yarra 2000 SEC column (3 µm, 145 Å pore 
size, 300 x 4.6 mm; Phenomenex Inc. Torrance, CA, USA) was then loaded onto the 
HPLC and equilibrated for 2 hrs in MilliQ, followed by 2 hrs equilibration in PBS. 
Approximately 10 µl of each CpG-OVA conjugate diluted 1 in 6 in PBS was injected 
into the column and run for 15 mins at a flow rate of 0.35 ml/min at 25 °C. UV detection 
was set to 260 nm and 280 nm. 3D spectral analysis was then performed using Agilent 





2.2 Immunological tests 
 
2.2.1 Animal acquisition 
 
Six to eight-week old male C57BL/6, OT-I and OT-II mice were sourced from the 
Hercus Taieri Research Unit (HTRU), University of Otago. All mice were specific 
pathogen free (SPF) and ethical approval was obtained for all mouse experiments by 
the University of Otago Animal Ethics Committee. 
 
2.2.2 Isolation of Bone marrow derived dendritic cells (BMDC)  
 
Femurs and tibiae of 6-8-week-old male C57BL/6 mice were extracted, stripped of 
surrounding tissue, and placed into a petri dish containing Dulbecco’s PBS (DPBS, 
Gibco by Life Technologies Corp, Grand Island, NY, USA) before transfer into a 
biological safety cabinet. Bones were then immersed in 70% ethanol on ice for 2 mins 
before being washed twice in DPBS in a six well plate. After washing, the epiphyses of 
each bone were cut using sterile scissors and shafts were flushed with DPBS + 5% 
Foetal Bovine Serum (FBS, Moregate Biotech, Bulimba, Australia) into a separate well. 
The bone marrow was collected and transferred to a 50 ml Falcon tube and spun at 250 
x g for 7 mins at 4 °C. Supernatant was then poured off and red blood cells were lysed 
with 3 ml ammonium chloride red blood cell (RBC) lysis buffer for 2 mins after 
resuspension. Cells were then washed in 30 ml DPBS + FBS to neutralise the lysis 
buffer and filtered through a 70 μm cell strainer (Corning Inc., Tewksbury, MA) into a 
new falcon tube. The cells were once again centrifuged at 250 x g for 7 mins at 20 °C. 




Iscove's Modified Dulbecco's Medium (cIMDM)(Gibco) + 5% FBS + 20 ng/ml 
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF; ProSpec, East 
Brunswick, NJ, USA) solution. Cells were then manually counted using a 
hemocytometer by adding 10 µl of cells to 90 μl of trypan blue and visualizing under a 
microscope at the 20x objective lens. Cells were then resuspended at 0.5 x 106 cells/ml 
in 24 ml and transferred to a six-well plate, 4 ml per well. This was incubated at 37 °C 
5% CO2. On day 3 cells were fed by replacing 2 ml of media with 2.5 ml of warm fresh 
media (cIMDM + 5% FBS + GM-CSF). 
 
2.2.3 Activation of bone marrow derived dendritic cells 
 
 
On day 6 of culture, BMDCs were collected by gently pipetting the media up and down, 
so as not to dislodge any adherent macrophages, and transferred to a 50 ml falcon tube. 
They were then centrifuged at 250 x g for 7 mins at 20 °C, supernatant discarded, and 
resuspended in 2 ml of cIMDM + 5% FBS + GM-CSF before counting via trypan blue 
method. Cells were then plated onto a U-bottom 96-well plate, at a concentration of 1 x 
106 cells, 200 μl per well for BMDCs or 1 x 105 cells, 100 μl per well for T cell co-
cultures, in triplicate per treatment. Cells were then pulsed with either OVA (3.5 μg/ml), 
CpG B (0.425 μM), CpG C (0.53 μM), OVA + CpG B, OVA + CpG C, CpG B conjugate 
(3.5 μg/ml), CpG C conjugate (3.5 μg/ml) or Lipopolysaccharide (LPS) (1 μg/ml). Cells 






2.2.4 Bone Marrow Dendritic Cell Flow Cytometry preparation 
 
After 24 hrs incubation, cells were spun down at 350 x g for 7 mins at 4 °C and 100 μl 
of supernatant from each well was transferred to a new 96-well plate and frozen at -20 
°C for use in cytokine assays. Remaining cells were resuspended by pipetting up and 
down and transferred into separate Fluorescent Assisted Cell Sorting (FACS) tubes. 
They were then topped up with 1 ml of PBS before being spun at 350 x g for 7 mins at 
20 °C. After spinning, supernatant was removed using a glass pipette via suction and 
cells were resuspended in remaining PBS and stained with 50 μl of fixable live/dead 
NIR dye on ice, for 15 mins in the dark. Following staining, the tubes were topped up 
with 1 ml of FACS buffer and spun at 350 x g for 7 mins at 20 °C. Supernatant was 
sucked off and cells were stained with 50 μl anti-CD16/32 Fc Block for 5 mins on ice 
followed by staining with 50 μl of CD86-PE, CD40-PE-Cy7, CD11c APC (as a 
dendritic cell marker) and MHC-II FITC master mix on ice for 15 mins in the dark. 
Dilutions of these antibodies is supplied in table 3. Following staining, cells were 
topped up with 1 ml of FACS buffer and spun at 350 x g for 7 mins at 20 °C. After 
removal of supernatant, 200 μl of FACS buffer was added to each tube and tubes 
vortexed to resuspend the cells. The cells were run on the Gallios flow cytometer 
(Beckman Coulter, Fullerton, CA, USA) and analysed using Kaluza version 1.6 







2.2.5 T cell isolation and co-culture 
 
Spleens isolated from OT-I, OT-II male mice were prepared into a single cell suspension 
by gently pushing them through a 70 μm cell strainer using the plunger of a sterile 5 ml 
syringe. The strainer was then rinsed using DPBS + 5% FBS to collect all cells in a 50 
ml Falcon tube before centrifugation at 300 x g for 7 mins at 4 °C. Supernatants were 
then poured off and cells were treated with 7 ml of ammonium chloride RBC lysis buffer 
before neutralization in 30 ml DPBS + 5% FBS. Cells were centrifuged (300 x g for 7 
mins at 4 °C), resuspended in 10 ml of MACs buffer (DPBS + 0.5% BSA + 25µM 
EDTA), and counted using trypan blue method. After cell count cells were centrifuged 
again at 300 x g for 7 mins at 4 °C before resuspension in 90 μl of MACS buffer per 107 
cells. Cells were then treated with 10 μl CD8α+, CD4+ micro beads (Miltenyi Biotech, 
Bergisch Gladbach, Germany) per 107 cells and incubated for 15 mins in an ice block. 
Every 5 mins, cells were inverted to ensure good mixing and interaction with the 
microbeads. After 15 mins, CD4+/CD8+ bead treated cells were washed in 15 ml MACS 
buffer and spun at 300 x g for 7 mins at 4 °C. Supernatant was then poured off and cells 
resuspended in 1 ml MACS buffer per 108 cells. Cells were then separated using the 
AutoMACS pro (Miltenyi Biotech) on the Possel-s setting with MACS running buffer 
(see appendix 1). Following cell sorting, the positive fraction was collected and counted 
using trypan blue. Cells were topped up with warm cIMDM + 5% FBS and centrifuged 
at 300 x g for 7 mins at 20 °C. Cells were then resuspended at 1 x 106 cells/ml and 3.6 
ml of this was then added at 100 μl/well (single co-culture) or 50 μl/well (double co-
culture) to BMDCs for use in cytokine assays Remaining cells were then spun at 300 x g 
for 7 mins at 4 °C and resuspended in cIMDM + 5% FBS. They were treated with 20 μM 




Life Technologies Corp) solution and left to react in the dark for 8 mins at room 
temperature. FBS was then added at equal amount to the cell suspension to quench the 
reaction and cells were washed three times in DPBS + 1% FBS spun at 300 x g for 7 
mins at 20 °C. Cells were counted using trypan blue method and resuspended at 1 x 106 
cells/ml in cIMDM + 5% FBS. From this suspension, 100 μl was added to each well of 
a BMDC culture. This was then incubated for 72 hrs at 37 °C 5% CO2.  
 
2.2.6 T cell Flow cytometry preparation 
 
After 72 hrs incubation, non-CFSE stained co-cultures were spun down at 350 x g for 7 
mins at 4 °C and 100 μl/ well of supernatant was transferred to a new 96-well plate and 
frozen at -20 °C for future use in cytokine assays. CFSE cells were suspended in their 
supernatant by pipetting up and down and then transferred into separate FACS tubes. 
They were then topped up with 1 ml of PBS before being spun at 350 x g for 7 mins at 4 
°C. After spinning, supernatant was poured off and cells resuspended in remaining PBS 
before staining with 50 μl of fixable live/dead zombie yellow stain on ice, for 15 mins in 
the dark. Cells were then topped up with 1 ml of PBS and spun again at 350 x g for 7 
mins at 4 °C. Supernatant was then poured off, and cells were then stained with 50 μl 
anti-CD16/32 Fc Block for 5 mins on ice followed by staining with 50 μl of CD3-PE 
Dazzle, CD8 APC and CD4 APC/CY7 also on ice for 15 mins in the dark. Dilutions of 
these antibodies is supplied in table 3. Stained cells were topped up with 1 ml of FACS 
buffer and spun at 350 x g for 7 mins at 4 °C, after removal of supernatant. FACS buffer 
was added to each tube (200 µl) and each was vortexed to resuspend the cells. These 




Table 3: FACS antibodies and dilutions 
Antibody Dilution Clone Manufacturer 
Live/Dead NIR violet 
Dye 
1:1000 - Life technologies 
Live/Dead Zombie 
Yellow Dye 
1:600 - Biolegend 
CD3-PE Dazzle 1:200 145-2C11 Biolegend 
CD4-APC/Cy7 1:800 GK1.5 Biolegend 
CD8α APC 1:200 53-6.7 Biolegend 
CD11c APC 1:800 N418 Biolegend 
CD40 PE/Cy7 1:200 3/23 Biolegend 
CD86 PE 1:400 GL-1 Biolegend 
CD335 PE/Cy7 1:100 29A1.4 Biolegend 
MHC-II FITC 1:800 M5/114.15.2 Biolegend 





2.2.7 Interferon gamma (IFN-ɣ) Enzyme Linked Immunosorbent 
Assay (ELISA) 
 
Wells of a 96-well ELISA plate were first coated with 50 μl of purified anti-mouse IFN-
ɣ primary antibody at a 1/250 dilution in coating buffer (0.1M NaHCO3 pH9.5) and 
incubated for 1 hr at 37℃. The buffer was then briefly flicked out and the plate washed 
by immersing in wash buffer (appendix 1) to fill the wells and then vigorously flicking 
out the contents into a sink. This was repeated 6 times before blotting on a paper towel 
to remove residual buffer. Plates were then treated with blocking buffer (PBS + 1% BSA) 
at 200 μl per well and incubated for 2 hrs at 37℃. Solution was then flicked off and the 
plate washed 6 times in wash buffer. Samples were then added to wells at 50 µl/well in 
triplicate. IFN-Y was added in duplicate to separate wells at 15 ng/ml followed by a two-
fold dilution series at concentrations of 10 ng/ml - 0 ng/ml. The plate was then incubated 
overnight at 4℃. The next day the plate was washed 6 times and 50 µl/well of 
biotinylated anti-IFN-ɣ antibody was added to each well at a 1/250 dilution in blocking 
buffer before incubation for 30 mins at 37℃. Following incubation, the plate was washed 
6 times and 100 μl/well of streptavidin-horse radish peroxidase (HRP) was added to each 
well at a 1/3000 dilution in blocking buffer. The plate was incubated at 37 ℃ for a further 
20 mins, washed 6 times and 100 μl/well of TMB substrate was added. The plate was 
then covered in aluminium foil to protect from light and left to react for 8-10 mins with 
colour development checked regularly. Once a clear colour change was visible in the 
standard wells, the reaction was stopped by adding 100 μl/well of 1N H2SO4 solution. 
The plate was then read at 450 nm on a microplate reader (Perkin Elmer) and standard 





2.2.8 Interferon alpha (IFN-α) ELISA 
 
Pre-coated IFN-α primary antibody ELISA 96-well plate supplied by Invitrogen was first 
washed twice by immersing each well in wash buffer for 15 seconds before flicking out 
the contents into a sink. The plate was then blotted dry using a paper towel and 50 μl of 
IFN-α Assay buffer was added to each well. Standards at concentrations of 2000, 1000, 
500, 250, 125, 62.5 and 31.3 pg/ml externally diluted in calibrator diluent were then 
added to 14 wells, 50 μl each. Calibrator diluent (50 μl) was also added to 2 wells to act 
as a blank. Diluted biotin-conjugate was then added at 50 μl to all well including the 
blanks and the plate was covered in adhesive film and left to incubate for 2 hrs at room 
temperature on a microplate shaker set at 400 rpm. Film was then removed, and plate 
washed 4 times as previously described. Streptavidin-HRP was then added at 100 μl per 
well to each of the wells before the plate was covered in film and placed on a microplate 
shaker for 1 hr. Film was then removed, plate washed 4 times and 100 μl of TMB 
substrate solution was added to each well to start the colour changing reaction. This was 
left to react for 15 mins under aluminium foil, to protect it from light, before being 
stopped via the addition of 100 μl of stop solution. The plate was then read at 450 nm 
using a microplate reader (Perkin Elmer) and concentration of IFN-α in each sample 
extrapolated from the standard curve produced. 
 
2.2.9 LegendPlex cytokine assays 
 
LegendPlex bead samples (85 μl) (TNF-ɑ, IL-1β, IL-12p70 and IL-6) (Biolegend) were 
added to 1860 μl of Assay buffer (Biolegend) to form a master mix of beads, each at a 1 




96-well V-bottom plate. LegendPlex standard was then added at 25 μl per well to 14 
wells to form the standard concentrations after a four-fold series dilution. Samples (25 
μl) were then added to the remaining wells. Finally, 25 μl of Legendplex bead master 
mix was then added to all wells and the plate was covered in tin foil and placed on a 
shaker for 2 hrs at room temperature at 800 rpm. Following incubation, the plate was 
centrifuged at 250 x g for 5 mins. The supernatant was then removed by flicking the plate 
over a sink in one fluid motion. The plate was then blotted dry and washed by adding 
200 μl of wash buffer to each well and placing on the shaker for 1-2 mins at 800 rpm. 
The plate was then centrifuged and washed once more before addition of 25 μl of 
detection antibodies at a ½ dilution. The plate was sealed, covered in aluminium foil and 
placed back on the shaker for 1 hr at room temperature, set to 800 rpm. After 1 hr, 25 μl 
of fluorescent antibody was added to each well and the plate was returned to the shaker, 
covered in aluminium foil for a further 1 hr. The plate was then removed and well 
contents transferred to individual FACS tubes for analysis on the flow cytometer. 
 
2.2.10 Statistical analysis 
 
All statistical analyses were performed using Graphpad prism software version 7.03 
(GraphPad Software, La Jolla, CA, USA). A one-way analysis of variance (ANOVA) 
with Tukey post hoc test was used in each immunological assay to compare the means 
of each treatment group. Error bars represent the standard error of the mean (SEM) and 














3.1 Synthesis and characterization of conjugates 
 
3.1.1 Generation of Gp100-CpG conjugates 
 
CpG oligonucleotides were successfully modified with either S-4FB or SS-4FB, with 
each producing MSRs between 0.8-1.2 (table 4). After addition of S-HyNic and gp100, 
the A345 nm was then measured using Nanodrop 1000. A345 nm readings were not 
detectable for any conjugate. Therefore, RP-HPLC, initially a method to purify the 




Table 4: Molar substitution rates of S-4FB/SS-4FB modified CpGs used for each conjugate 
 
Conjugate MSR 
CpG B-S-gp100 (25-33) 1.06 
CpG B-SS-gp100 (25-33) 0.84 
CpG B-S-gp100 (19-39) 0.81 
CpG B-SS-gp100 (19-39) 0.93 
CpG C-S-gp100 (25-33) 1.18 
CpG C-SS-gp100 (25-33) 1.19 
CpG C-S-gp100 (19-39) 1.04 






3.1.2 RP-HPLC analysis of individual gp100 peptides and CpGs 
 
Before RP-HPLC analysis of each conjugate, it was clear that the ability to distinguish 
Gp100 peptides and CpG B/C ODNs was necessary to accurately identify each conjugate. 
Thus initially, gp100 peptides and CpGs were run through the C18 column at increasing 
concentrations (see methods 2.1.5) for 45 minutes. Both gp100 peptides had UV 
absorbance (~2-10 mAU) detectable at both 210, 214, 220 and 280 nm. At the lowest 
concentration of 50 µg/ml, gp100 peptides eluted at 13.8 mins (25-33) and 16.8 mins 
(19-39) respectively (figure 4a). Prominent peaks which distinguished gp100 peptides 
from surrounding products within the 280 nm absorbance range was not observed until a 
concentration 100 ug/ml. Higher concentrations of gp100 presented with greater 
absorbance (~14 mAU) (See supplementary). CpG oligonucleotides were not identified 
until a concentration of 10 μM eluting at approximately 12.8 minutes (CpG B) and 7.58 



















Figure 4: RHPLC analysis of individual Gp100 and CpG oligonucleotides. (A) 50 µg/ml Gp100 peptides (25-33) 
(top) and (19-39) (bottom)were run through the HPLC at a flow rate of 0.5 ml/min for 25mins.Uv detection was set 
to 280 nm. Products eluted at approx. 13.8mins and 16.8 mins respectively. (B) 10 µM CpG B (top) and CpG C 









3.1.3 RP-HPLC analysis of Gp100 conjugates 
 
Gp100 conjugates were each loaded onto the HPLC based off the concentration of gp100 
used during the final reaction step. Each combination of CpG ODN, linker type and 
gp100 peptide produced an abundance of absorbance readings at elution times ranging 
from 5 to 20 minutes on the HPLC making gp100 conjugates unable to be identified 
accurately. Individual gp100 peptides were identifiable in most conjugate samples at an 
elution time of between 13.3-13.8 mins alongside other products with unique elution 
times but similar UV absorbance at 220 and 280 nm. The figure below shows the elution 
profiles of CpG B-SS-gp100 (25-33) (figure 5a) and CpG B-SS-gp100 (19-39) (figure 






















Figure 5: RP HPLC profiles of CpG B reversible gp100 conjugates: Each conjugate was loaded onto the HPLC at 
a flow rate of 0.5 ml/min for 35 mins. UV absorbance was measured at 210,214,220 and 280 nm (A) Elution profiles 
of reversible CpG B linked to gp100 (19-39) at 220 nm and 280 nm. (B) Elution profiles of reversible CpG B linked 




3.1.4 Spin filtration effectively removes unconjugated products 
 
To visualise the final reaction, linkage of gp100 to modified CpG, a time course was 
performed using RP-HPLC. Samples of ~10 µl were taken from modified CpG B upon 
introduction of Gp100 (25-33) at 1 min, 2 hrs and at 2 hrs after 5 rounds of spin filtration 
at 13,000 x g for 15 mins at 4°C. All samples were then analysed on the HLPC to identify 
any changes that indicate the reaction had occurred. Based off both absorbance and 3D 
spectral analysis, each sample had little change. Absorbance readings pre-and post-spin 
filtration showed a ten-fold reduction in absorbance of almost all products after spin 
filtration. Several products, which had eluted at 5.1 mins, 18.8 mins and 31.1 mins with 














Figure 6: RP HPLC elution profiles of CpG B-SS-gp100 (25-33) at 260 nm, flow rate 0.5 ml/min. (A) Elution 
profiles at 1 min after addition of gp100 (B) Elution profile 2 hrs after gp100 addition, before spin filtration. (C) 












3.1.5 Switch to OVA system 
 
The inability to accurately identify gp100-CpG conjugates in each sample via RP-HPLC 
meant that purification and thus, use for immunological assays, was not possible. 
Although further methodologies could have been tested, due to time constraints, this 
study switched to using the OVA system that has previously been characterized in our 
laboratory for CpG B(100). Ovalbumin is a 44 kDa chicken egg protein that is often used 
in as a model antigen in immunological tests due its T cell-dependant immunogenicity in 
mice and well established transgenic mice strains. Additional tests would now aim to 
produce reversible OVA conjugates linked to either CpG B or CpG C and compare their 




3.1.6 Purification of OVA 
 
With gp100 conjugates unsuccessful, experiments switched to using model antigen 
‘OVA’ to compare CpG B/C immunogenicity within reversible conjugates. Though 
stable in lyophilised form, dissolved OVA is prone to aggregation and formation of 
complexes of variable molecular weight (109). To ensure all OVA used in conjugation 
and immunological assays was of consistent size, SEC was performed to purify the 
protein. Using the Superdex™ 200 10/300 GL SEC column (Ge Healthcare) on a 
Shimadzu high performance liquid chromatograph, OVA monomer was successfully 
purified at an elution time of 27-32.5 mins based off its absorbance at 280 nm (Figure 7) 
with higher molecular weight aggregates eluting at 7.5-17.5 mins and 20-26 mins. Pure 
























Figure 7: Purification of Ovalbumin: Dissolved OVA was run through a Superdex™ 200 10/300 GL SEC column for 45 
mins at UV detection of 280 nm in Modification buffer. Monomeric OVA eluted between 27-32.5 mins with aggregates 




Figure 8: Purification of CpG B-SS-OVA conjugate: CpG B-SS-OVA was injected at a volume of 500 µl and run 
for 45 mins in PBS on a Superdex™ 200 10/300 GL SEC column. UV detection was set to 260 nm. The resulting 
product eluted at 25-30 mins with unreacted CpG B eluting at 32-37 minutes. 
3.1.7 Production of reversible OVA-CpG conjugates 
 
After purification, OVA monomer (2.75 mg/ml) was first modified with S-HyNic linker 
and its MSR measured via Nanodrop. At an MSR of 1.2, the reaction was deemed 
sufficient for further modification. CpG oligonucleotides were modified with SS-4FB, 
producing an MSR of 1.1 each. With both constituents at sufficient MSRs, modified 
CpGs were added to modified OVA in the presence of turbolink buffer and left to react 
overnight. The presence of aniline in the buffer acts as a catalyst for hydrazine bond 
formation. Given a molecular weight difference of over ~6 kDa between single OVA and 
each conjugate, the resulting product was then purified using SEC. Both conjugates 
eluted at 25-30 mins detected at 260 nm, with unreacted products eluting at 30-35 mins. 
Approximately 3 ml of each pure conjugate was collected in a 15 ml Falcon tube upon 




























3.1.8 Analysis of reversible OVA-CpG conjugates 
 
Though conjugates had been purified using preparative size exclusion chromatography, 
their characterization required additional testing using analytical SEC. This would allow 
analysis of each conjugates’ absorbance profile at both 260 nm, (peak absorbance of 
CpG) and 280 nm (peak absorbance of OVA). For this reason, each conjugate was diluted 
1 in 6 in PBS and run individually through the Yarra 2000 SEC column. Figure 9 below 
shows the result of both conjugates. CpG B-SS-OVA eluted at 7-9 mins with absorbance 
at both 260 and 280 nm. CpG C-SS-OVA eluted between 6-8.5 mins indicative of its 
larger molecular weight difference ~0.6 kDa compared to the CpG B conjugate. CpG C-
SS-OVA showed similar absorbance profile to CpG B-SS-OVA at 260 and 280 nm and 























Figure 9: Analytical SEC and 3D spectral analysis of CpG, OVA and CpG-OVA conjugates (A) SEC of CpG B(0.47 
µM)(top) and OVA (1 mg/ml)(bottom) at 260 nm.(B) SEC of  CpG B-SS-OVA at 260 and 280 nm. (C) SEC of CpG 





3.1.9 Characterisation of CpG-OVA conjugates 
 
Upon purification, the conjugation ratio of CpG-OVA conjugates was determined using 
a combination of A345 nm measurement via Nanodrop 1000 and QuantiT assay. A345 
nm measurement of each conjugate was used to visualise the presence of bis-aryl 
hydrazone as described for gp100 conjugation. QuantiT assay was then used to determine 
the concentration of OVA within each conjugate based on extrapolation from a standard 
curve of BSA protein standards. Both values were then combined to assess the number 
of CpG oligonucleotides per OVA protein. For CpG B-SS-OVA this value was 4.25, 
whilst CpG C-SS-OVA produced a ratio of 5.3. The concentration of individual CpGs 
for BMDC and T cell activation, proliferation and cytokine assays were matched to 





3.2 Immunological assays 
 
3.2.1 BMDC activation by CpG-OVA conjugates 
 
BMDCs were pulsed with either OVA, individual CpG B/C, OVA + CpG B/C mixtures, 
CpG B/C conjugates or LPS for 24 hrs at 37 °C and then stained and analysed using flow 
cytometry. Live, CD11c+ cells were deemed BMDCs. BMDCs did not show any 
significant difference in their expression of MHC-II, CD86 or CD40 when pulsed with 











Figure 10: BMDC activation: BMDCs were pulsed for 24 hrs with either OVA, CpG B/C, OVA + CpG B/C mixtures, 
CpG B/C-SS-OVA, LPS 1 µg/ml or left untreated. Mean fluorescence intensity (MFI) of cell surface markers (A) 




Figure 11: Representative-gating strategy for BMDC flow cytometry analysis: 1x106 BMDCs were 




3.2.2 BMDCs cytokine production by CpG-OVA conjugates 
 
Using LegendPlex (Biolegend) and ELISA, cell culture supernatants from 24 hrs pulsed 
DCs were measured for production of pro-inflammatory cytokines TNF-α, IL-12p70, IL-
1β, IL-6 and IFN-α. Both CpG B-SS-OVA and CpG C-SS-OVA induced production of 
all cytokines however there was no significant difference compared to OVA + CpG B/C 
mixtures. LPS treatment showed a significant difference between all treatments for both 











Figure 12: BMDC cytokine production: BDMCs were pulsed with either OVA, OVA + CpG B/C, CpG B/C, CpG B/C 
conjugate or LPS 1 µg/ml for 24 hrs at 37°C. (A) TNF-α (left), IL-12p70 (right), (B) IL-1β, (left) IL-6 (right) and (C) 
IFN-α cytokines were then measured using a LegendPlex assay or ELISA (IFN-α) on cell culture supernatants. 




3.2.3 CD4+ T cell proliferation and IFN-γ production after BMDC co-
culture  
 
Treated BMDCs were co-cultured with CD4+ T cells for 72 hrs and analysed on the flow 
cytometer. T cells were sorted based on size and then gated for live, single cells which 
were CD3+CD4+. CFSE+ CD4+ cells were then analysed to determine percentage 
proliferation. Both conjugates induced CD4+ T cell proliferation, which was statistically 
different from the untreated group. IFN-γ production was measured via ELISA, both 
conjugates induced significantly greater IFN-γ production than untreated and individual 
CpG B and CpG C treatments. In addition, CpG C-SS-OVA also showed significantly 
greater proliferation than CpG C + OVA and OVA treatments. In both CD4+ 
proliferation and IFN-γ assays there was no statistical difference between individual 
conjugates. 
 
Figure 13: CD4+ T cell proliferation and IFN-γ production: (A) Percentage of CD4+ proliferation in each T cell 
treatment group after 72hrs BMDC co-culture (B) Measurement of IFN-γ in CD4+ T cell culture supernatants 
after 72 hrs BMDC co-culture. Graphs are each the result of three independent experiments. Statistical significance 






   
Figure 14: Representative-gating strategy for CD4+ T cells: T cells were stained with zombie yellow live dead 




3.2.4 CD8+ T cell proliferation and IFN-γ production after BMDC co-
culture  
 
After 72 hrs of co-culture, T cells were sorted based on size and then gated for live, single 
cells, which were CD3+CD8+. CFSE+ CD8+ cells were then analysed to determine 
percentage proliferation. CD8+ T cells had significant proliferation in both conjugates, 
OVA, OVA + CpG B/C and SIINFEKL treatments compared to untreated and CpG B/C 
treatments.  IFN-γ production was significantly greater in both conjugate treatments and 
SIINFEKL than all other treatments. There was no significant difference between 
conjugate and SIINFEKL treatments in either assay. 
. 
 
Figure 15: CD8+ T cell proliferation and IFN-γ production: (left) Percentage of CD8+ proliferation in each T cell 
treatment group after 72hrs BMDC co-culture (right) Measurement of IFN-γ in CD8+ T cell culture supernatants 
after 72 hrs BMDC co-culture. Graphs are representative of three independent experiments. Statistical 






Figure 16: Representative-gating strategy for CD8+ T cells: T cells were stained with zombie yellow live dead dye, CD8α 




3.2.5 T cell proliferation and IFN-γ production after 
CD8+/CD4+/BMDC co-culture 
 
Anti-tumour immune response require interaction between multiple T cell types. In many 
adoptive cell therapies, it has been shown that CD4+ and CD8+ cultured at a 1:1 ratio 
elicit strong cytotoxic responses to tumours. Therefore, to investigate how each T cell 
population interacts to elicit anti-tumour immune response to each conjugate; CD4+ and 
CD8+ T cells were both co-cultured with dendritic cells at a 5:5:1 ratio. T cells were then 
sorted using flow cytometry, gating for live, single cells which were CD3+ and either 
CD4+ or CD8+ respectively. Analysis revealed that CD8+ T cells dominated the culture 
after 72 hrs with greater proliferation than CD4+ T cells. There was no significant 
difference in CD4+ T cell proliferation between any treatments. CD8+ T cells showed 
significantly greater proliferation in OVA, OVA + CpG B/C, and both conjugate 
treatments compared to untreated and individual CpG B/C. There was no statistical 
difference between these treatments groups however. CpG B and C conjugates, as well 
as SIINFEKL, all produced significantly greater IFN-γ than individual CpG and OVA 
treatments and mixtures. No statistical difference was observed between each conjugate 










Figure 17: CD4+ and CD8+ T cell proliferation and IFN-γ production after CD8+/CD4+/BMDC co-culture: (A) 
Percentage of CD4+ proliferation (left) Percentage of CD8+ proliferation (right)(B) IFN-γ levels in co-culture 
supernatants. Graphs are representative of three independent experiments. Statistical significance p <0.05. Error 






Figure 18: Representative-gating strategy for CD8+ and CD4+ T cells: T cells were sorted for live, single cells, 
which were CD3 positive, and then either CD4 or CD8 positive. CFSE positive CD4+ and CD8+ cells were then 
















4.1  Discussion 
 
The initial aims of this study were to utilise a novel conjugation strategy to link clinically 
relevant, gp100 melanoma peptides (25-33) and (19-39) to TLR agonists CpG B and CpG 
C and measure their ability to stimulate anti-tumour responses. Conjugates were first 
produced using a solution chemistry-based two-linker strategy designed by Solulink. 
Resulting conjugates were then analysed using RP-HPLC to determine the success of the 
reactions and purify the resulting conjugate products. Though this study was successful 
in producing gp100 conjugates, they were unable to be purified using RP-HPLC. 
Therefore, experiments were switched to using the model antigen ‘OVA’ in conjugates, 
which already had a well-established purification protocol using SEC. This enabled the 
immunostimulatory effects of each CpG in a reversible vaccine construct to be compared. 
Using a combination of cell culture, flow cytometry, LegendPlex and ELISA, results 
demonstrated that both CpG B and CpG C reversible OVA conjugates stimulate 
comparable anti-tumour responses in dendritic cells and both CD4+ and CD8+ T cell 
populations. Specifically, upregulation of co-stimulatory markers and pro-inflammatory 
cytokines in BMDCs as well as increased proliferation and IFN-γ production in T cell 
co-cultures were observed. More importantly, both conjugates stimulated a greater 
immune response than CpG B/C + OVA mixtures; which model a variety of formulations 
currently trialled in cancer vaccine based immunotherapy. Each conjugate treatment 
significantly increased T cell IFN-γ production which is characteristic of effector 
function, and plays a key role in anti-tumour immunity. This highlighted the role of 
reversible formulations in increasing effector responses and validated the use of CpG 
oligonucleotides as effective anti-tumour vaccine adjuvants. To fully compare the ability 





4.1.1 Difficulties with RP-HPLC purification of Gp100 peptide 
conjugates 
 
RP-HPLC is used in the purification of many chemical compounds including those 
involved in drug and vaccine production (110). Though individual gp100 peptides and 
CpG oligonucleotides were identified using RP-HPLC, its use to identify gp100 
conjugates was not sensitive enough to distinguish them from other potential products in 
the sample. These may include degraded peptide variants, unconjugated CpG-S-HyNic 
and CpG-SS-HyNic. Samples were each analysed using UV absorbance, their elution 
time relative to the individual unreacted CpG and gp100 counterparts, and their 3D 
spectral absorbance. Though each sample had many peaks, or suspected conjugates, it 
was unclear which were the true conjugates. Many samples showed a strong absorbance 
at 280 nm indicative of gp100 peptide presence, though they had an absence of 260 nm 
absorbance, characteristic of CpG. Many samples also had absorbance at 260-300 nm, 
which were indistinguishable from each other, making it difficult to draw solid 
conclusions as to their structure. The same could also be seen for absorbance at 345 nm, 
the indicator of bis-aryl hydrazone bond formation, which links gp100 to modified CpG. 
It is likely that excess/residual aromatic hydrazine (S-HyNic) and aldehyde (S-4FB, SS-
4FB) linkers may have affected absorbance readings, along with the sensitivity of the UV 
detector on the Agilent system. As well the presence of background peptides, it may be 
possible that the sample/conjugate itself was unstable and degraded before detection. 
Aggregation of samples may have also affected absorbance readings and these could also 
explain the variation in elution times of structures with similar 260 nm and 280 nm 
absorbance. 
Interestingly at a higher concentration, CpG B oligonucleotide (500 µM) revealed an 




minutes seen at lower concentrations (figure 1b). As this concentration was only 
measured once in this study, it is likely that this was a technical error within the column, 
which may be due to blockage of the column with air bubbles or other products. The CpG 
B reading was also undetectable in all conjugate samples supporting this. However, 
another suggestion as to why it wasn’t detectable could simply be its low concentration 
within conjugate structures due to low free amino group (NH2) availability in each gp100 
(2 amino groups per peptide). As well as this, the higher concentration CpG B favoured 
absorbance at 280 nm over 260 nm. Its reference as pure CpG therefore made 
identification of each conjugate based on 260 nm absorbance challenging as this reading 
was not significantly different from gp100 peptide absorbance at 280 nm. In future 
experiments individual CpG B and CpG C oligonucleotides should be analysed in 
triplicate to ensure accurate elution times for reference in conjugate samples. The 
similarities in each conjugates RP-HPLC result also suggested that the reaction may not 
have occurred. Given the susceptibility of the NHS-ester groups to hydrolysis, I 
suggested that the addition of S-HyNic and gp100 steps be combined to reduce any S-
HyNic hydrolysis that may be preventing efficient conjugation. This way, once S-HyNic 
bound to modified CpG, it could almost instantaneously bind to gp100. This would 
however, lead to new products such as CpG-HyNic from unmodified CpG residing in the 
sample and SS-4FB-modified gp100 from residual aldehydes in solution. In a repeated 
experiment, using CpG B with reversible SS-4FB linker, samples were run through the 
HPLC at 2 mins after the addition of gp100 and S-HyNic, then after 2 hrs reaction time, 
before spin filtration and then once more after spin filtration. There was insignificant 
difference between the two earliest time points, suggesting that the reaction either did not 
occur, or occurred rapidly. It is likely that a variety of factors may have influenced this 




reaction occurring during preparation would therefore not be recorded. As well as this, 
samples taken after the 2 mins of gp100 addition were frozen at -20°C as a method to 
stop the reaction until analysis. It is highly likely that the reaction may have completed 
before the sample was fully frozen or resumed and completed after thawing. In future 
tests, the sample should be immediately analysed on the HPLC instead of freezing and 
running each sample at the same time. Despite failure to observe the reaction, comparison 
of samples before and after spin filtration did highlight the importance of this step in the 
product purification. Spin filtration removed/reduced many background products in the 
sample (excess linker and degraded peptides etc). Despite this, there were still too many 
candidates which could have been the true conjugates, with almost identical absorbance 
at 260 and 280 nm. In future experiments, liquid chromatography/mass spectrometry 
(LC/MS) or MALDI-TOF mass spectroscopy could be used to fully identify each 
conjugate, as done for several other conjugates mentioned in the literature (111-113). 
Conjugates could then be run on RP-HPLC to purify at a later stage. Alternatively, RP-
HPLC may also not be the best method to purify the conjugates and alternatives such as 
Native polyacrylamide gel electrophoresis (Native PAGE) could be investigated. Native 
PAGE separates products based on their relative electrical charge and may be more 
effective if the conjugates have significantly different net charges to their individual 
counterparts. Ultimately, given the efficiency in terms of time of RP-HPLC, a 
combination of both Native PAGE and RP-HPLC could be used to purify the conjugates 
with PAGE as the initial purification, followed by RP-HPLC to identify them singularly 
and their elution times. RP-HPLC could then be solely used for purification of each 
conjugate in future/repeated experiments. 
With RP-HPLC purification unsuccessful, studies switched to using model antigen 




had already been studied in our laboratory using SEC. Therefore, pre-existing 
methodology could be used and altered for the production of our reversible OVA-CpG 
B and OVA-CpG C conjugates.  
 
4.1.2 CpG B/C-SS-OVA conjugates requires additional 
characterization 
 
Although conjugation between CpG B/C and OVA was successful, quantification and 
determination of the conjugation ratio produced unexpected results. Both modification 
of CpG and OVA produced MSRs well within ranges deemed successful (between 0.8-
1.2). However, measurement of OVA concentration within conjugates using Quant-It, 
combined with A345 nm readings led to conjugation ratios much higher than expected. 
The MSR of OVA indicated that the maximum conjugation ratio possible for both 
conjugates was 1.4. Interestingly results from conjugation ratio calculation revealed 
ratios of 4.6 and 5.3 for CpG B and CpG C respectively. In immunological assays this 
was controlled for, although it remains unclear if this was the true conjugation ratio. It is 
likely that operator errors during the assay may have played a role in this finding and led 
to overestimation of the conjugation ratio. In future experiments, Quant-iT tests should 
be repeated to minimise this. Additionally, the use of OVA standards at differing 
concentrations instead of the BSA standards provided could strengthen the use of this 
assay by directly comparing concentrations of the protein of interest. Results from SEC 
support this, as conjugation ratios as high as 5.3 would produce conjugates of a much 
greater molecular weight and thus earlier elution times. Both conjugates analysed 
through the Yarra2000 eluted at similar times to previous studies which had a conjugation 




CpG B/C concentrations in individual and OVA mixtures may mask the significance of 
each conjugates immunostimulatory effect. 
With OVA-CpG conjugates produced and purified, the next steps in this study aimed to 
assess their Immunostimulatory effects on BMDCs and T cells. Therefore, to achieve 
this, experiments shifted to cell culture. 
 
4.1.3  Immunostimulatory effects of CpG-OVA conjugates on BMDCs 
 
MHC and co-stimulatory molecules such as CD80/86 and CD40 play a key role in co-
ordinating both tumour-specific T cell activation and proliferation (33, 36, 55, 114, 115). 
It is well documented that upregulation of these proteins occurs when antigen presenting 
cells such as DCs are pulsed with toll-like receptor agonists such as CpG (114, 116). This 
study observed no significant difference between each treatment; which supports 
previous studies using CpG B conjugates (100). Pro-inflammatory cytokine production 
was also not significantly different although both CpG conjugates showed a trend to 
higher levels of IL-1β and IL-12p70 than other treatments excluding LPS. It is important 
to note that IL-12p70 is known to induce differentiation and proliferation of CD8+ T 
cells and direct CD4+ T cells to a Th1 phenotype (60, 115, 117, 118). This cytokine also 
increases T cell and NK cell production of IFN-γ (57, 77). Though IL-1β does not directly 
stimulate T cells, it is an important inducer of inflammation and has effects on many cells 
including endothelial cells, macrophages and other DCs. Therefore, full assessment of 
the influence of this IL-1β production on the anti-tumour immune response would require 
in vivo testing. 
Remarkably, LPS in this study did not stimulate significant increases in IL-1β, IL-12p70 




the literature and suggests that there may be issues in cell culture preparation (42, 119). 
It is possible that our BMDCs cultured for 7 days were not sufficiently matured and thus 
less sensitive to LPS stimulation. It is likely that operator errors during the LegendPlex 
assay may also explain this, including insufficient washing of residual beads and short 
incubation times. These should therefore, all be repeated in future experiments. 
 
Interestingly, there was also no significant change in IFN-α, a cytokine that should have 
been higher in both LPS and CpG C treatments based off previous literature (114, 120). 
One suggestion is that the IFN-α was already degraded by the time the ELISA was 
performed (supernatants were frozen at -20°C until use) or rapidly taken up by other 
BMDCs before detection. Measurements may have become inconsistent as supernatant 
storage time varied and all samples were measured on the same ELISA plate at one time. 
This suggests that simple experimental errors could explain the result including 
premature stoppage of the colour reaction; however, standard dilutions were measured 
successfully indicating the ELISA kit itself was not at fault. Another likely reason could 
simply be the culturing conditions. BMDCs cultured with GM-CSF may favour 
differentiation into the conventional DC (cDC) phenotype, which functions more in 
antigen presentation than cytokine production, especially in the case of IFN-α. Further 
experiments should direct attention to pulsing DC cultures containing Plasmacytoid DCs 
(pDC), the chief producers of type 1 interferon, as well as cDCs to assess the effect of 
CpG C conjugates. This can be done by either pulsing splenic DCs, which consist of all 
DC subsets including pDCs, or addition of Fms-related tyrosine kinase 3 ligand (Flt3L) 
into the BMDC culture media to promote generation of DCs that mimic that of the murine 




experiments should aim to identify these in culture, perhaps via their exclusive 
expression of cell marker B220 and low CD11c expression compared to cDCs (124).  
 
4.1.4 Effects of conjugate pulsed BMDCs on CD4+ T cells 
 
CD4+ T cells are crucial in co-ordinating anti-tumour immune responses. In particular, 
they play a key role in the production of IFN-γ which promotes MHC expression on 
tumours, activates tissue-resident macrophages and promotes CD4+ T cell polarisation 
to T helper 1 phenotype. CD4+ T cells are also chief producers of IL-2, which induces 
proliferation in CD4+ T cells, CD8+ T cells and Natural Killer cells, all of which 
contribute to the anti-tumour immune response. The presence of IL-2 and IFN-γ within 
patient serum is often linked to positive disease outcome and therefore the ability to 
stimulate CD4+ T cell proliferation and their cytokine production, is of great interest in 
immunotherapy (125-127).  
In this study, CD4+ T cells co-cultured with BMDCs showed antigen-specific expansion 
characterised by the greater percentage of proliferation in treatments containing OVA in 
both full protein and peptide forms. Interestingly, the results of this study did not support 
previous findings, with conjugates not showing significant differences in CD4+ IFN-γ 
production compared to CpG + OVA mixtures(100). It is however, important to consider 
that this study had conjugation ratios over double that of previous work. As well as this, 
CpG concentrations were matched to account for this difference. It is likely that the 
higher CpG concentrations in mixtures may have resulted in increased overall uptake and 
thus increased activation of BMDCs. Uptake of the conjugates was not affected as it was 




With no difference observed in MHC-II expression within BMDC cultures, it is likely 
that both co-stimulatory molecules and pro-inflammatory cytokines expressed by 
BMDCs also played a key role in this result. It is however important to consider that 
CD86 expression was also not statistically different between any of the treatments tested. 
Therefore, other co-stimulatory markers not measured in this study may be responsible 
for this result such as CD80. To fully characterise any differences in MHC-II expression, 
measurements of specific OVA peptide 323-339 presentation on MHC-II complexes 
would need to be performed, perhaps via anti-MHC-II-OVA323-339 fluorescent 
antibodies, which could then be analysed using flow cytometry. It is also possible that 
the OVA within conjugates had increased loading onto MHC-II, whilst other treatments 
favoured the loading of endogenous self-peptides, which did not stimulate the OVA-
specific T cells, onto MHC-II. 
Pro-inflammatory cytokines such as IL-12p70 could also explain the increased T cell 
numbers. IL-12p70 is well documented as a potent activator of CD4+ T cells and inducer 
of their proliferation. In addition, IL-12p70 is also known to enhance CD4+ T cell IFN-
γ production. Despite this, it is unlikely that IL-12p70 was the sole contributor to this 
response. Other cytokines not measured in this study such as IL-18, are also expressed 
by CpG stimulated BMDCs and polarise CD4+ T cells to a Th1-IFN-γ producing 
phenotype. IL-18 is also known to synergize with IL-12p70 to induce CD4+ IFN-γ 
production in an antigen-independent manner in humans (128). This result shows that 
reversible OVA conjugates can effectively stimulate CD4+ T cells in vitro. In relation to 
the original aims of this study it seems likely that this conjugation strategy may also 





4.1.5 Effects of conjugate pulsed BMDCs on CD8+ T cells 
 
CD8+ T cells play a key role in anti-tumour immunity through various mechanisms 
including death receptor ligation and IFN-γ release (60, 78, 129). Results from this study 
show that both conjugates induce similar levels of T cell proliferation and IFN-γ release, 
regardless of CpG adjuvant used. Curiously, CD8+ T cells had both higher proliferation 
percentages than CD4+ T cells and produced a greater volume of IFN-γ, indicative of 
effector function. One explanation for this result is that the conjugates may favour 
presentation of OVA peptides onto MHC-I molecules, either by inducing trafficking of 
OVA to the cytoplasm or via upregulation of proteins involved in cross-presentation such 
as TAP. This is unlikely, as co-cultures of DCs with both CD4+ and CD8+ T cells 
induced similar proliferation levels in treatments with OVA 323-339 which only loads 
onto MHC-II. Future tests could examine the levels of MHC-I loaded with SIINFEKL 
peptide on dendritic cells determine its contribution to this result. This could be measured 
using fluorescent antibodies analysed via flow cytometry. Similar to CD4+ T cells, IL-
12p70 could also explain the increase in CD8+ T cell numbers. Other cytokines such as 
IL-18 are also known to synergise with IL-12p70, as previously mentioned (115, 118). 
Further experiments to measure these cytokines would clarify this result. Intriguingly, in 
co-cultures containing both CD4+ and CD8+ T cells, CD8+ cell numbers dominated the 
culture at 72 hrs and had greater proliferation than their CD4+ counterparts despite a 
lower ratio of each T cell relative to BMDCs. This supports the idea of MHC-I 
favourability, though it is just as likely that stimulation with IL-2 produced by activated 







4.1.6 Effects of conjugates on CD4+ and CD8+ T cells in co-culture 
 
Generating an effective anti-tumour immune response requires multiple immune cell 
populations. It has already been highlighted that CD4+ T cells play a crucial role in 
enhancing CD8+ T cell effector function in many studies. Although typical T cell co-
cultures use at least a 1:2 ratio of CD4+ to CD8+ T cells, many adoptive cell therapies 
have used CD4+ and CD8+ T cell at a 1:1 ratio and shown enhanced T cell cytotoxic 
function(130, 131). To investigate if this effect translates in each conjugate, CD4+ and 
CD8+ T cells were co-cultured with BMDCs at a ratio of 5:5:1. Results showed a 
significant expansion of CD8+ T cells within the culture at 72 hrs. Interestingly, CD4+ 
T cells showed little change in proliferation, even in treatments groups which favoured 
MHC-II presentation such as OVA 323-339. It is well documented that CD4+ T cells 
enhance CD8+ T cell and NK cell proliferation through production of IL-2 and this is 
likely the cause of the CD8+ T cell expansion (28, 132). The supernatants of conjugate 
treated cultures also showed greatly increased IFN-γ compared to OVA + CpG B/C 
mixtures. This is likely a result of both initial CD4+ production and CD8+ production 
after differentiation into CTLs brought on by BMDC cytokines including IL-12p70. In 
addition, early IFN-γ production by CD4+ T cells may have enhanced MHC-I expression 
on BMDCs leading to increase CD8+ stimulation. 
In summary, both conjugates appear as strong inducers of T cell proliferation and IFN-γ 
production. With suspected increases in MHC loading of OVA peptides and synergy 
between pro-inflammatory cytokines including IL-12p70 and IL-18, it is likely that this 
enhanced response is the result of both antigen-dependant and anti-independent 





4.1.7 Future immunological tests 
 
Results from this study have demonstrated that both CpG B and CpG C use, within 
reversible vaccine constructs, elicits a robust peptide-specific T cell response in vitro. 
Though this is a powerful predictor of the vaccines’ efficacy, in vivo studies should be 
investigated to fully compare each conjugate. These may include testing the ability of T 
cells to kill target cells using an in vivo cytotoxicity assay, or full tumour trial in a mouse 
model. Additional in vitro tests could be performed to investigate the effect of these 
conjugates on other immune cells such as Natural Killer cells, which are known to be 
activated by IFN-α as well as IL-12p70 (77). NK cells are also a source of IFN-γ and thus 
have great therapeutic potential for the treatment of tumours. The effect of conjugates 
could also be assessed on their ability to stimulate B cells, another adaptive immune cell 
which acts in both antigen presentation and antibody production. B cells give an 
alternative method of antigen presentation, which may synergize with presentation by 
cDCs. Their production of polyclonal antibodies can also act to ‘tag’ tumours for cell-
mediated killing by Natural Killer cells. Finally, the in vitro results gathered in this study 
indicate that both conjugates have immense potential as therapeutic cancer vaccines, as 
either a monotherapy or a combined therapy. Therefore testing in combination with either 
Checkpoint Blockade or Adoptive Cell Therapy could further characterise its 




Cancer remains an ongoing challenge for clinicians and researchers alike. Though many 
immunotherapies have shown promise in treating cancer, it is unlikely that cancer 




do however; remain a useful treatment option, which can be combined with other 
treatments to enhance their therapeutic effect. Its ability to boost tumour-specific T cell 
responses make it a great candidate for combinational therapy with Checkpoint Blockade 
as well as Adoptive Cell Therapy. Overall, improvements in cancer vaccine design and 
testing through the choice of immune adjuvant and tumour peptide seem set to increase 
its importance in cancer treatment, especially in the realm of combinational 
immunotherapy. In sum, this study illustrated the numerous challenges present in 
production and testing of soluble cancer vaccines. Although purification of the gp100 
conjugates was unsuccessful, experiments using OVA successfully compared each CpG 
type within reversible conjugates. Results showed a similar level of immune stimulation 
with significantly increased T cell responses compared to individual OVA protein and 
CpGs. Given the importance of T cell responses in anti-tumour immunity and the clinical 
relevance of gp100 as a melanoma-associated antigen, it remains of high interest to 
investigate the effect of these CpGs within gp100 constructs. Both CpG classes appear, 
as strong candidates for use in cancer vaccines and with careful experimental design and 
consideration of these challenges in both purification and immunological assays, the 
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Appendix 1: Buffers and Recipes 
 
Modification buffer  
14.2 g Na2HPO4  
8.76 g NaCl   
pH 8.0  
  
Conjugation buffer  
14.2 g Na2HPO4  
8.76 g NaCl   
pH 6.0  
  
MES buffer  
0.96 g MES  
250 ml MilliQ  
  
2-HP solution  
0.00045 g 2-HP  
50 ml MES buffer  








2-SBA solution  
0.00052 g 2-SBA  
50 ml MES buffer  
Protect from light  
 
Turbolink catalyst buffer  
15 ml conjugation buffer 
139.65 µl aniline   
pH 6.0  
  
10 x Phosphate Buffered Saline (PBS) 
80 g NaCl  
11.35 g Na2HPO4  
2 g KCl  
2 g KH2PO4  
1L MilliQ 
 
Red Cell Lysis Buffer 
4.15 g NH4Cl 
0.5 g KHCO3 
0.0186 g EDTA 
500 ml  MilliQ 





10 x FACS buffer  
100 ml 10 x PBS  
10 g BSA  
1g NaN3 
7.44g EDTA  
1L MilliQ 
  
MACS buffer  
292.24 mg EDTA  
5 g DPBS  
2.5 mg BSA  
Top up with MilliQ to 500 ml  
pH 7.2  
  
MACS running buffer  
292.24 mg EDTA  
5 g DPBS  
0.5 mg BSA  
Top up with MilliQ to 500 ml  







ELISA Coating buffer  
0.42 g NaHCO3  
50 ml MilliQ  
  
ELISA Wash buffer  
200 ml 10 X PBS  
1 ml Tween 20  
MilliQ 1.8L 
  
ELISA Blocking buffer  
100 ml PBS  
1 g BSA   
  
LegendPlex Wash buffer  
25 ml of 20 X Legendplex wash buffer (Biolegend) 























Figure 19 Supplementary 1: RP-HPLC analysis of CpG B stable conjugates. (A) Analysis of CpG B-S-gp100 (25-


































Figure 20 Supplementary 2: RP-HPLC analysis of CpG C reversible and stable gp100 conjugates. (A) Analysis of 
CpG C-SS-gp100 (19-39) at 220 nm (top) and 280 nm (bottom) (B) Analysis of CpG C-SS-gp100 (25-33) at 220 
nm (top) and 280 nm (bottom) (C) Analysis of CpG C-S-gp100 (19-39) at 220 nm (top) and 280 nm (bottom) (D) 



























Figure 21 Supplementary 3: Purification of CpG C-SS-OVA conjugate: CpG C-SS-OVA was injected at a 
volume of 500 µl and run for 45 mins in PBS on a Superdex™ 200 10/300 GL SEC column. UV detection 






























Figure 22: BMDC Unstained control gating: Untreated BMDCs were harvested from cell culture supernatants 
and directly run on the Galios flow cytometer. This formed the basis of the BMDC gating strategy used on stained 
samples 
  
